File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Raloxifene, tamoxifen and vascular tone

TitleRaloxifene, tamoxifen and vascular tone
Authors
Issue Date2007
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEP
Citation
Clinical And Experimental Pharmacology And Physiology, 2007, v. 34 n. 8, p. 809-813 How to Cite?
Abstract1. Oestrogen deficiency causes progressive reduction in endothelial function. Despite the benefits of hormone-replacement therapy (HRT) evident in earlier epidemiological studies, recent randomized trials of HRT for the prevention of heart disease found no overall benefit. Instead, HRT users had higher incidences of stroke and heart attack. Most women discontinue HRT because of its many side-effects and/or the increased risk of breast and uterine cancer. This has contributed to the development of selective oestrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, as alternative oestrogenic agents. 2. A SERM is a molecule that binds with high affinity to oestrogen receptors but has tissue-specific effects distinct from oestrogen, acting as an oestrogen agonist in some tissues and as an antagonist in others. Clinical and animal studies suggest multiple cardiovascular effects of SERMs. For example, raloxifene lowers serum levels of cholesterol and homocysteine, attenuates oxidation of low-density lipoprotein, inhibits endothelial-leucocyte interaction, improves endothelial function and reduces vascular smooth muscle tone. 3. Available evidence suggests that raloxifene and tamoxifen are capable of acting directly on both endothelial cells and the underlying vascular smooth muscle cells and cause a multitude of favourable modifications of the vascular wall, which jointly contribute to improved local blood flow. The outcome of the Raloxifene Use for the Heart (RUTH) trial will determine whether raloxifene, currently approved for the treatment of post-menopausal osteoporosis, could substitute for HRT in alleviating cardiovascular symptoms in post-menopausal women. © 2007 The Authors.
metadata.dc.description.uriFrontiers in Research Reviews: Hormones and Vascular Function
Persistent Identifierhttp://hdl.handle.net/10722/134680
ISSN
2012 Impact Factor: 2.16
2015 SCImago Journal Rankings: 0.944
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, FPen_HK
dc.contributor.authorTsang, SYen_HK
dc.contributor.authorWong, CMen_HK
dc.contributor.authorYung, LMen_HK
dc.contributor.authorChan, YCen_HK
dc.contributor.authorLeung, HSen_HK
dc.contributor.authorYao, Xen_HK
dc.contributor.authorHuang, Yen_HK
dc.date.accessioned2011-07-05T08:24:13Z-
dc.date.available2011-07-05T08:24:13Z-
dc.date.issued2007en_HK
dc.identifier.citationClinical And Experimental Pharmacology And Physiology, 2007, v. 34 n. 8, p. 809-813en_HK
dc.identifier.issn0305-1870en_HK
dc.identifier.urihttp://hdl.handle.net/10722/134680-
dc.description.abstract1. Oestrogen deficiency causes progressive reduction in endothelial function. Despite the benefits of hormone-replacement therapy (HRT) evident in earlier epidemiological studies, recent randomized trials of HRT for the prevention of heart disease found no overall benefit. Instead, HRT users had higher incidences of stroke and heart attack. Most women discontinue HRT because of its many side-effects and/or the increased risk of breast and uterine cancer. This has contributed to the development of selective oestrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, as alternative oestrogenic agents. 2. A SERM is a molecule that binds with high affinity to oestrogen receptors but has tissue-specific effects distinct from oestrogen, acting as an oestrogen agonist in some tissues and as an antagonist in others. Clinical and animal studies suggest multiple cardiovascular effects of SERMs. For example, raloxifene lowers serum levels of cholesterol and homocysteine, attenuates oxidation of low-density lipoprotein, inhibits endothelial-leucocyte interaction, improves endothelial function and reduces vascular smooth muscle tone. 3. Available evidence suggests that raloxifene and tamoxifen are capable of acting directly on both endothelial cells and the underlying vascular smooth muscle cells and cause a multitude of favourable modifications of the vascular wall, which jointly contribute to improved local blood flow. The outcome of the Raloxifene Use for the Heart (RUTH) trial will determine whether raloxifene, currently approved for the treatment of post-menopausal osteoporosis, could substitute for HRT in alleviating cardiovascular symptoms in post-menopausal women. © 2007 The Authors.en_HK
dc.description.uriFrontiers in Research Reviews: Hormones and Vascular Function-
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEPen_HK
dc.relation.ispartofClinical and Experimental Pharmacology and Physiologyen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAtherosclerosis - drug therapy - physiopathologyen_HK
dc.subject.meshBlood Vessels - drug effects - metabolismen_HK
dc.subject.meshCardiovascular Agents - pharmacology - therapeutic useen_HK
dc.subject.meshCardiovascular Diseases - drug therapy - physiopathologyen_HK
dc.subject.meshCerebrovascular Circulation - drug effectsen_HK
dc.subject.meshCollateral Circulation - drug effectsen_HK
dc.subject.meshCoronary Circulation - drug effectsen_HK
dc.subject.meshEndothelium, Vascular - drug effects - metabolismen_HK
dc.subject.meshEstrogen Replacement Therapyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshNitric Oxide - metabolismen_HK
dc.subject.meshPulmonary Circulation - drug effectsen_HK
dc.subject.meshRaloxifene - pharmacology - therapeutic useen_HK
dc.subject.meshSelective Estrogen Receptor Modulators - pharmacologyen_HK
dc.subject.meshTamoxifen - pharmacology - therapeutic useen_HK
dc.subject.meshVasodilation - drug effectsen_HK
dc.titleRaloxifene, tamoxifen and vascular toneen_HK
dc.typeArticleen_HK
dc.identifier.emailChan, YC:yauchi@graduate.hku.hken_HK
dc.identifier.authorityChan, YC=rp01502en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1440-1681.2007.04684.xen_HK
dc.identifier.pmid17600563-
dc.identifier.scopuseid_2-s2.0-34347338584en_HK
dc.identifier.hkuros155340-
dc.identifier.hkuros203435-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34347338584&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume34en_HK
dc.identifier.issue8en_HK
dc.identifier.spage809en_HK
dc.identifier.epage813en_HK
dc.identifier.eissn1440-1681-
dc.identifier.isiWOS:000247575500021-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridLeung, FP=8615375300en_HK
dc.identifier.scopusauthoridTsang, SY=7102255908en_HK
dc.identifier.scopusauthoridWong, CM=36631362300en_HK
dc.identifier.scopusauthoridYung, LM=13807768200en_HK
dc.identifier.scopusauthoridChan, YC=7403676116en_HK
dc.identifier.scopusauthoridLeung, HS=13104316400en_HK
dc.identifier.scopusauthoridYao, X=7402529434en_HK
dc.identifier.scopusauthoridHuang, Y=7501573013en_HK
dc.identifier.citeulike1421075-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats